Symbols / RNAZ $8.60 -1.04% TransCode Therapeutics, Inc.
RNAZ Chart
About
TransCode Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing drugs and diagnostics for treating and identifying cancer. The company's lead therapeutic candidate comprises TTX-MC138 that targets microRNA-10b, a master regulator of metastatic cell viability in various cancers comprising breast, pancreatic, ovarian, colon cancer, glioblastomas, and others. Its preclinical programs include TTX-siPDL1, an siRNA-based modulator of programmed death-ligand 1 and two indication agnostic programs; TTX-RIGA, an RNA- based agonist of the retinoic acid-inducible gene I targeting activation of innate immunity in the tumor microenvironment; TTX-CRISPR, a CRISPR/Cas9-based therapy platform for the repair or elimination of cancer-causing genes inside tumor cells; and TTX-mRNA, an mRNA-based platform for the development of cancer vaccines that activate cytotoxic immune responses against tumor cells. TransCode Therapeutics, Inc. has strategic collaboration agreement with The University of Texas M. D. Anderson Cancer Center. The company was incorporated in 2016 and is based in Boston, Massachusetts.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 7.89M |
| Enterprise Value | 5.05M | Income | -27.13M | Sales | — |
| Book/sh | 1.71 | Cash/sh | 3.09 | Dividend Yield | — |
| Payout | 0.00% | Employees | 7 | IPO | — |
| P/E | — | Forward P/E | -14.33 | PEG | — |
| P/S | — | P/B | 5.03 | P/C | — |
| EV/EBITDA | -0.30 | EV/Sales | — | Quick Ratio | 1.02 |
| Current Ratio | 1.60 | Debt/Eq | — | LT Debt/Eq | — |
| EPS (ttm) | -236.52 | EPS next Y | -0.60 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2025-04-15 16:00 | ROA | -232.54% |
| ROE | -17.63% | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 916.97K |
| Shs Float | 832.42K | Short Float | 7.45% | Short Ratio | 3.90 |
| Short Interest | — | 52W High | 22.04 | 52W Low | 6.08 |
| Beta | 1.50 | Avg Volume | 216.72K | Volume | 1.36K |
| Target Price | — | Recom | None | Prev Close | $8.69 |
| Price | $8.60 | Change | -1.04% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
—
Mean price target
2. Current target
$8.60
Latest analyst target
3. DCF / Fair value
$-180.92
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$8.60
Low
—
High
—
Mean
—
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2025-04-16 | main | HC Wainwright & Co. | Buy → Buy | $10 |
| 2025-03-13 | reit | HC Wainwright & Co. | Buy → Buy | $20 |
| 2025-02-07 | reit | HC Wainwright & Co. | Buy → Buy | $20 |
| 2025-02-06 | reit | HC Wainwright & Co. | Buy → Buy | $20 |
| 2024-12-18 | main | HC Wainwright & Co. | Buy → Buy | $20 |
| 2024-11-15 | reit | HC Wainwright & Co. | Buy → Buy | $3 |
| 2024-10-24 | reit | HC Wainwright & Co. | Buy → Buy | $3 |
| 2024-09-06 | reit | HC Wainwright & Co. | Buy → Buy | $3 |
| 2024-08-15 | reit | HC Wainwright & Co. | Buy → Buy | $3 |
| 2024-05-29 | reit | HC Wainwright & Co. | Buy → Buy | $3 |
| 2024-05-16 | reit | HC Wainwright & Co. | Buy → Buy | $3 |
| 2024-04-16 | reit | HC Wainwright & Co. | Buy → Buy | $3 |
| 2024-04-03 | reit | HC Wainwright & Co. | Buy → Buy | $3 |
- Responsive Playbooks and the RNAZ Inflection - Stock Traders Daily Sun, 05 Apr 2026 19
- TransCode Secures Exclusive, Worldwide, Fully Paid-Up Royalty-Free License to Develop and Commercialize a Next-Generation Oncolytic Immunotherapy Platform in an All-Stock Transaction Underscoring the Company's Dedication to Improving the Lives of - PR Newswire ue, 03 Mar 2026 08
- RNAZ (RNAZ) delays 2025 Form 10-K after $25M preferred placement and acquisition - Stock Titan ue, 31 Mar 2026 20
- TransCode Therapeutics Delays 2025 Annual Filing - TipRanks Wed, 01 Apr 2026 02
- TransCode Therapeutics stock soars after promising glioblastoma study - Investing.com ue, 06 Jan 2026 08
- TransCode Therapeutics, Inc. (RNAZ) Competitors - Meyka hu, 02 Apr 2026 23
- RNAZ PE Ratio & Valuation, Is RNAZ Overvalued - Intellectia AI Sat, 04 Apr 2026 12
- TransCode Therapeutics (RNAZ) announces the acquisition of Polynoma and a $25 Million strategic financing by a subsidiary of CK Life Sciences to form a first-in-class unique immuno-oncology and metastatic prevention oncology company - PR Newswire Wed, 08 Oct 2025 07
- New cancer approach uses tumor RNA to trigger immune attack in cells - Stock Titan Mon, 23 Feb 2026 08
- TransCode Therapeutics To Acquire Polynoma, Receive $25M Investment To Advance Key Asset - Stocktwits Wed, 08 Oct 2025 07
- TransCode Therapeutics’ TTX-MC138 Excites Market with Promising Glioblastoma Data - StocksToTrade hu, 05 Feb 2026 08
- All You Need to Know About TransCode Therapeutics (RNAZ) Rating Upgrade to Buy - Yahoo Finance Fri, 18 Apr 2025 07
- Understanding the Setup: (RNAZ) and Scalable Risk - Stock Traders Daily Wed, 25 Mar 2026 18
- Colorectal cancer study to test RNA drug TTX-MC138 after standard treatment - Stock Titan hu, 05 Feb 2026 08
- RNAZ Forecast — Price Prediction for 2026. Should I Buy RNAZ? - Intellectia AI Wed, 04 Jun 2025 08
Insider Transactions
No recent insider transactions.
Financials
Statement View
| Line Item | Trend | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Revenue |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Operating Revenue |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Operating Expense |
|
15.14
-18.16%
|
18.50
+5.37%
|
17.55
+198.89%
|
5.87
|
| Research And Development |
|
9.71
-20.85%
|
12.26
+19.85%
|
10.23
+271.55%
|
2.75
|
| Selling General And Administration |
|
5.95
-16.78%
|
7.15
-14.84%
|
8.40
+147.31%
|
3.40
|
| General And Administrative Expense |
|
5.95
-16.78%
|
7.15
-14.84%
|
8.40
+147.31%
|
3.40
|
| Other Gand A |
|
5.95
-16.78%
|
7.15
-14.84%
|
8.40
+147.31%
|
3.40
|
| Other Operating Expenses |
|
-0.52
+43.22%
|
-0.92
+14.57%
|
-1.08
-288.18%
|
-0.28
|
| Total Expenses |
|
15.14
-18.16%
|
18.50
+5.37%
|
17.55
+198.89%
|
5.87
|
| Operating Income |
|
-15.14
+18.16%
|
-18.50
-5.37%
|
-17.55
-198.89%
|
-5.87
|
| Total Operating Income As Reported |
|
-15.66
+19.35%
|
-19.42
-4.21%
|
-18.63
-202.93%
|
-6.15
|
| EBITDA |
|
-16.19
+9.90%
|
-17.97
-3.09%
|
-17.43
-159.99%
|
-6.71
|
| Normalized EBITDA |
|
-15.20
+15.44%
|
-17.97
-3.09%
|
-17.43
-199.06%
|
-5.83
|
| Reconciled Depreciation |
|
0.53
+3.50%
|
0.52
+424.05%
|
0.10
+132.18%
|
0.04
|
| EBIT |
|
-16.73
+9.53%
|
-18.49
-5.46%
|
-17.53
-159.81%
|
-6.75
|
| Total Unusual Items |
|
-1.00
|
0.00
|
0.00
+100.00%
|
-0.88
|
| Total Unusual Items Excluding Goodwill |
|
-1.00
|
0.00
|
0.00
+100.00%
|
-0.88
|
| Special Income Charges |
|
0.00
|
0.00
|
0.00
+100.00%
|
-0.00
|
| Net Income |
|
-16.75
+9.66%
|
-18.55
-5.59%
|
-17.56
-156.67%
|
-6.84
|
| Pretax Income |
|
-16.75
+9.66%
|
-18.55
-5.59%
|
-17.56
-156.67%
|
-6.84
|
| Net Non Operating Interest Income Expense |
|
-0.62
-1131.05%
|
-0.05
-337.23%
|
-0.01
+87.74%
|
-0.09
|
| Interest Expense Non Operating |
|
0.03
-52.03%
|
0.06
+74.76%
|
0.03
-66.36%
|
0.10
|
| Net Interest Income |
|
-0.62
-1131.05%
|
-0.05
-337.23%
|
-0.01
+87.74%
|
-0.09
|
| Interest Expense |
|
0.03
-52.03%
|
0.06
+74.76%
|
0.03
-66.36%
|
0.10
|
| Interest Income Non Operating |
|
0.00
-87.06%
|
0.01
-74.11%
|
0.02
+2973.80%
|
0.00
|
| Interest Income |
|
0.00
-87.06%
|
0.01
-74.11%
|
0.02
+2973.80%
|
0.00
|
| Other Income Expense |
|
-1.00
|
—
|
—
|
-0.88
|
| Gain On Sale Of Security |
|
-1.00
|
—
|
—
|
-0.87
|
| Tax Rate For Calcs |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Tax Effect Of Unusual Items |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Net Income Including Noncontrolling Interests |
|
-16.75
+9.66%
|
-18.55
-5.59%
|
-17.56
-156.67%
|
-6.84
|
| Net Income From Continuing Operation Net Minority Interest |
|
-16.75
+9.66%
|
-18.55
-5.59%
|
-17.56
-156.67%
|
-6.84
|
| Net Income From Continuing And Discontinued Operation |
|
-16.75
+9.66%
|
-18.55
-5.59%
|
-17.56
-156.67%
|
-6.84
|
| Net Income Continuous Operations |
|
-16.75
+9.66%
|
-18.55
-5.59%
|
-17.56
-156.67%
|
-6.84
|
| Normalized Income |
|
-15.76
+15.02%
|
-18.55
-5.59%
|
-17.56
-194.36%
|
-5.97
|
| Net Income Common Stockholders |
|
-16.79
+9.49%
|
-18.55
-5.59%
|
-17.56
-156.67%
|
-6.84
|
| Otherunder Preferred Stock Dividend |
|
0.03
|
0.00
|
—
|
—
|
| Diluted EPS |
|
-1,319.92
+95.17%
|
-27,313.84
+97.36%
|
-1,033,233.41
-156.67%
|
-402,552.88
|
| Basic EPS |
|
-1,319.92
+95.17%
|
-27,313.84
+97.36%
|
-1,033,233.41
-156.67%
|
-402,552.88
|
| Basic Average Shares |
|
0.01
+1773.05%
|
0.00
+3894.12%
|
0.00
+0.00%
|
0.00
|
| Diluted Average Shares |
|
0.01
+1773.05%
|
0.00
+3894.12%
|
0.00
+0.00%
|
0.00
|
| Diluted NI Availto Com Stockholders |
|
-16.79
+9.49%
|
-18.55
-5.59%
|
-17.56
-156.67%
|
-6.84
|
| Gain On Sale Of PPE |
|
0.00
|
0.00
|
0.00
+100.00%
|
-0.00
|
| Total Other Finance Cost |
|
0.60
|
—
|
—
|
—
|
| Line Item | Trend | 2023-12-31 |
|---|---|---|
| Total Assets |
|
5.17
|
| Current Assets |
|
4.46
|
| Cash Cash Equivalents And Short Term Investments |
|
2.77
|
| Cash And Cash Equivalents |
|
2.77
|
| Cash Financial |
|
2.77
|
| Receivables |
|
0.00
|
| Other Receivables |
|
—
|
| Prepaid Assets |
|
0.54
|
| Other Current Assets |
|
1.15
|
| Total Non Current Assets |
|
0.71
|
| Net PPE |
|
0.60
|
| Gross PPE |
|
0.87
|
| Accumulated Depreciation |
|
-0.26
|
| Machinery Furniture Equipment |
|
0.38
|
| Other Properties |
|
0.48
|
| Non Current Deferred Assets |
|
—
|
| Non Current Prepaid Assets |
|
0.11
|
| Total Liabilities Net Minority Interest |
|
3.53
|
| Current Liabilities |
|
3.49
|
| Payables And Accrued Expenses |
|
3.05
|
| Current Accrued Expenses |
|
3.05
|
| Current Debt And Capital Lease Obligation |
|
0.41
|
| Current Capital Lease Obligation |
|
0.41
|
| Current Deferred Liabilities |
|
0.03
|
| Current Deferred Revenue |
|
0.03
|
| Total Non Current Liabilities Net Minority Interest |
|
0.04
|
| Long Term Debt And Capital Lease Obligation |
|
0.04
|
| Long Term Capital Lease Obligation |
|
0.04
|
| Stockholders Equity |
|
1.64
|
| Common Stock Equity |
|
1.64
|
| Capital Stock |
|
0.00
|
| Common Stock |
|
0.00
|
| Preferred Stock |
|
0.00
|
| Share Issued |
|
0.00
|
| Ordinary Shares Number |
|
0.00
|
| Treasury Shares Number |
|
0.00
|
| Additional Paid In Capital |
|
48.06
|
| Retained Earnings |
|
-46.42
|
| Total Equity Gross Minority Interest |
|
1.64
|
| Total Capitalization |
|
1.64
|
| Working Capital |
|
0.96
|
| Invested Capital |
|
1.64
|
| Total Debt |
|
0.45
|
| Capital Lease Obligations |
|
0.45
|
| Net Tangible Assets |
|
1.64
|
| Tangible Book Value |
|
1.64
|
| Derivative Product Liabilities |
|
0.00
|
| Dueto Related Parties Current |
|
—
|
| Non Current Accrued Expenses |
|
—
|
| Line Item | Trend | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Operating Cash Flow |
|
-13.34
+26.22%
|
-18.07
-14.67%
|
-15.76
-199.28%
|
-5.27
|
| Cash Flow From Continuing Operating Activities |
|
-13.34
+26.22%
|
-18.07
-14.67%
|
-15.76
-199.28%
|
-5.27
|
| Net Income From Continuing Operations |
|
-16.75
+9.66%
|
-18.55
-5.59%
|
-17.56
-156.67%
|
-6.84
|
| Depreciation Amortization Depletion |
|
0.53
+3.50%
|
0.52
+424.05%
|
0.10
+132.18%
|
0.04
|
| Depreciation |
|
0.53
+3.50%
|
0.52
+424.05%
|
0.10
+132.18%
|
0.04
|
| Depreciation And Amortization |
|
0.53
+3.50%
|
0.52
+424.05%
|
0.10
+132.18%
|
0.04
|
| Other Non Cash Items |
|
—
|
—
|
—
|
0.00
|
| Stock Based Compensation |
|
1.70
+63.95%
|
1.04
+162.29%
|
0.40
+112.55%
|
0.19
|
| Operating Gains Losses |
|
1.54
|
—
|
—
|
0.88
|
| Gain Loss On Investment Securities |
|
1.54
|
—
|
—
|
0.87
|
| Gain Loss On Sale Of PPE |
|
—
|
—
|
0.00
-100.00%
|
0.00
|
| Change In Working Capital |
|
-0.35
+67.52%
|
-1.08
-182.69%
|
1.31
+179.56%
|
0.47
|
| Change In Receivables |
|
0.00
-100.00%
|
0.36
+200.00%
|
-0.36
|
0.00
|
| Change In Prepaid Assets |
|
0.41
+11.76%
|
0.36
+351.25%
|
-0.14
+92.41%
|
-1.90
|
| Change In Payables And Accrued Expense |
|
-0.34
+73.53%
|
-1.30
-170.29%
|
1.84
-21.23%
|
2.34
|
| Change In Accrued Expense |
|
—
|
—
|
0.00
-100.00%
|
0.06
|
| Change In Payable |
|
—
|
—
|
1.84
-19.31%
|
2.29
|
| Change In Account Payable |
|
—
|
—
|
1.84
-19.31%
|
2.29
|
| Change In Other Working Capital |
|
-0.00
-106.09%
|
0.03
+188.63%
|
-0.03
-200.00%
|
0.03
|
| Change In Other Current Assets |
|
0.00
+100.00%
|
-0.11
|
0.00
|
—
|
| Change In Other Current Liabilities |
|
-0.41
+2.85%
|
-0.42
|
0.00
|
—
|
| Investing Cash Flow |
|
-0.02
+38.89%
|
-0.04
+64.72%
|
-0.10
+59.92%
|
-0.25
|
| Cash Flow From Continuing Investing Activities |
|
-0.02
+38.89%
|
-0.04
+64.72%
|
-0.10
+59.92%
|
-0.25
|
| Net PPE Purchase And Sale |
|
-0.02
+38.89%
|
-0.04
+64.72%
|
-0.10
+59.92%
|
-0.25
|
| Purchase Of PPE |
|
-0.02
+38.89%
|
-0.04
+64.72%
|
-0.10
+60.40%
|
-0.25
|
| Sale Of PPE |
|
—
|
—
|
0.00
-100.00%
|
0.00
|
| Capital Expenditure |
|
-0.02
+38.89%
|
-0.04
+64.72%
|
-0.10
+60.40%
|
-0.25
|
| Financing Cash Flow |
|
16.40
+3.09%
|
15.91
+265542.41%
|
0.01
-99.98%
|
25.52
|
| Cash Flow From Continuing Financing Activities |
|
16.40
+3.09%
|
15.91
+265542.41%
|
0.01
-99.98%
|
25.52
|
| Net Issuance Payments Of Debt |
|
—
|
—
|
—
|
0.00
|
| Issuance Of Debt |
|
—
|
—
|
—
|
0.00
|
| Long Term Debt Issuance |
|
—
|
—
|
—
|
0.00
|
| Net Long Term Debt Issuance |
|
—
|
—
|
—
|
0.00
|
| Net Common Stock Issuance |
|
16.40
+3.09%
|
15.91
|
0.00
-100.00%
|
26.34
|
| Proceeds From Stock Option Exercised |
|
—
|
0.00
-100.00%
|
0.01
-79.54%
|
0.03
|
| Net Other Financing Charges |
|
—
|
—
|
—
|
-0.85
|
| Changes In Cash |
|
3.04
+238.29%
|
-2.20
+86.12%
|
-15.86
-179.30%
|
20.00
|
| Beginning Cash Position |
|
2.77
-44.30%
|
4.97
-76.14%
|
20.83
+2415.15%
|
0.83
|
| End Cash Position |
|
5.81
+109.97%
|
2.77
-44.30%
|
4.97
-76.14%
|
20.83
|
| Free Cash Flow |
|
-13.36
+26.24%
|
-18.11
-14.16%
|
-15.86
-187.29%
|
-5.52
|
| Interest Paid Supplemental Data |
|
0.02
-49.40%
|
0.03
-11.46%
|
0.04
+107.69%
|
0.02
|
| Income Tax Paid Supplemental Data |
|
—
|
—
|
—
|
0.00
|
| Change In Interest Payable |
|
—
|
—
|
0.00
-100.00%
|
0.06
|
| Common Stock Issuance |
|
16.40
+3.09%
|
15.91
|
0.00
-100.00%
|
26.34
|
| Issuance Of Capital Stock |
|
16.40
+3.09%
|
15.91
|
0.00
-100.00%
|
26.34
|
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
- 8-K2026-03-03 View
- 8-K2026-02-23 View
- 8-K2026-02-05 View
- 8-K2026-01-06 View
- 8-K2025-12-22 View
- 8-K2025-12-11 View
- 10-Q2025-11-14 View
- 8-K2025-10-27 View
- 8-K2025-10-14 View
- 8-K2025-10-08 View
- 8-K2025-10-03 View
- 8-K2025-09-02 View
- 10-Q2025-08-14 View
- 8-K2025-06-13 View
- 10-Q2025-05-14 View
- 8-K2025-05-07 View
- 8-K2025-05-05 View
- 8-K2025-05-02 View
- 8-K2025-04-21 View
- 10-K2025-04-15 View
Trades
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|
Posts
| Published | Title | Author | Category |
|---|